This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17ß-hydroxysteroid dehydrogenase (17ß-HSD) such as 17ß-HSD type 1, type 2 or type 3 enzyme.